| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 75 | 2023 | 1643 | 4.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 62 | 2024 | 1558 | 3.640 |
Why?
|
| Leukemia, Myeloid, Acute | 51 | 2024 | 3620 | 2.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 115 | 2024 | 11854 | 2.240 |
Why?
|
| Hodgkin Disease | 37 | 2020 | 1386 | 2.080 |
Why?
|
| Myelodysplastic Syndromes | 33 | 2024 | 1399 | 2.050 |
Why?
|
| Asparaginase | 21 | 2024 | 240 | 1.650 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 28 | 2024 | 1428 | 1.580 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 16 | 2023 | 384 | 1.480 |
Why?
|
| Mutation | 91 | 2024 | 30230 | 1.370 |
Why?
|
| Gene Expression Regulation, Leukemic | 25 | 2021 | 654 | 1.230 |
Why?
|
| Doxorubicin | 46 | 2024 | 2229 | 1.200 |
Why?
|
| Cancer Vaccines | 22 | 2024 | 1042 | 1.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 37 | 2024 | 5711 | 1.090 |
Why?
|
| Bone Marrow Transplantation | 45 | 2023 | 2709 | 1.050 |
Why?
|
| Venous Thromboembolism | 16 | 2024 | 1881 | 1.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 27 | 2023 | 1376 | 0.970 |
Why?
|
| Prednisone | 26 | 2024 | 1568 | 0.920 |
Why?
|
| Vincristine | 31 | 2024 | 1040 | 0.900 |
Why?
|
| Anemia, Sickle Cell | 12 | 2024 | 1065 | 0.880 |
Why?
|
| Cyclophosphamide | 36 | 2024 | 2226 | 0.860 |
Why?
|
| Lymphoma, Follicular | 17 | 2016 | 460 | 0.840 |
Why?
|
| Proto-Oncogene Proteins c-myc | 13 | 2021 | 997 | 0.830 |
Why?
|
| Antigens, Neoplasm | 20 | 2022 | 1999 | 0.830 |
Why?
|
| Sickle Cell Trait | 2 | 2021 | 86 | 0.820 |
Why?
|
| Remission Induction | 44 | 2024 | 2407 | 0.820 |
Why?
|
| Disease-Free Survival | 66 | 2024 | 6856 | 0.800 |
Why?
|
| Sulfonamides | 10 | 2024 | 1980 | 0.790 |
Why?
|
| Humans | 613 | 2024 | 768298 | 0.770 |
Why?
|
| Chromosome Aberrations | 21 | 2021 | 1780 | 0.770 |
Why?
|
| Myeloproliferative Disorders | 8 | 2022 | 614 | 0.760 |
Why?
|
| Proto-Oncogene Proteins | 28 | 2024 | 4526 | 0.740 |
Why?
|
| B-Lymphocytes | 29 | 2023 | 4785 | 0.740 |
Why?
|
| Cytarabine | 19 | 2024 | 697 | 0.670 |
Why?
|
| Neoplasm Proteins | 21 | 2021 | 3609 | 0.670 |
Why?
|
| CD8-Positive T-Lymphocytes | 21 | 2024 | 4647 | 0.670 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2023 | 9433 | 0.660 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 17 | 2018 | 892 | 0.660 |
Why?
|
| Neoplasm, Residual | 14 | 2020 | 1019 | 0.650 |
Why?
|
| Lymphoma, B-Cell | 19 | 2019 | 945 | 0.650 |
Why?
|
| Leukemia | 12 | 2024 | 1526 | 0.640 |
Why?
|
| Hematopoiesis | 17 | 2023 | 2058 | 0.640 |
Why?
|
| Anticoagulants | 19 | 2023 | 4842 | 0.630 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 13 | 2017 | 683 | 0.620 |
Why?
|
| Antineoplastic Agents | 45 | 2021 | 13696 | 0.620 |
Why?
|
| Female | 373 | 2024 | 397050 | 0.610 |
Why?
|
| Neoplasms, Second Primary | 16 | 2024 | 1060 | 0.610 |
Why?
|
| Vinblastine | 7 | 2019 | 488 | 0.600 |
Why?
|
| Hematologic Neoplasms | 12 | 2024 | 1906 | 0.600 |
Why?
|
| Male | 337 | 2024 | 364870 | 0.600 |
Why?
|
| Tumor Suppressor Protein p53 | 15 | 2024 | 2950 | 0.590 |
Why?
|
| Antibiotics, Antineoplastic | 8 | 2023 | 677 | 0.590 |
Why?
|
| Survival Rate | 64 | 2024 | 12870 | 0.590 |
Why?
|
| Prognosis | 94 | 2024 | 30020 | 0.580 |
Why?
|
| Middle Aged | 272 | 2024 | 223463 | 0.570 |
Why?
|
| Anemia | 5 | 2023 | 1520 | 0.570 |
Why?
|
| Adult | 271 | 2024 | 223622 | 0.570 |
Why?
|
| Neoplasms | 39 | 2024 | 22389 | 0.560 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 15 | 2017 | 695 | 0.560 |
Why?
|
| Gene Expression Profiling | 42 | 2024 | 9508 | 0.560 |
Why?
|
| Gene Expression Regulation, Neoplastic | 32 | 2021 | 8628 | 0.560 |
Why?
|
| Osteonecrosis | 5 | 2019 | 230 | 0.540 |
Why?
|
| Aged | 205 | 2024 | 171544 | 0.530 |
Why?
|
| Lymphoma | 10 | 2023 | 1907 | 0.520 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2018 | 230 | 0.510 |
Why?
|
| Polymorphism, Genetic | 18 | 2013 | 4250 | 0.510 |
Why?
|
| Vidarabine | 8 | 2015 | 337 | 0.510 |
Why?
|
| Dioxygenases | 6 | 2024 | 351 | 0.510 |
Why?
|
| T-Lymphocytes | 28 | 2024 | 10266 | 0.500 |
Why?
|
| Graft vs Host Disease | 16 | 2024 | 3043 | 0.500 |
Why?
|
| Transplantation, Homologous | 28 | 2024 | 4834 | 0.500 |
Why?
|
| Plateletpheresis | 3 | 2019 | 38 | 0.490 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2022 | 4411 | 0.480 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2024 | 1508 | 0.480 |
Why?
|
| Pyrimidines | 16 | 2019 | 3048 | 0.470 |
Why?
|
| Drug Resistance, Neoplasm | 20 | 2021 | 5335 | 0.470 |
Why?
|
| Apoptosis | 33 | 2021 | 9506 | 0.460 |
Why?
|
| DNA-Binding Proteins | 26 | 2024 | 9618 | 0.460 |
Why?
|
| Methotrexate | 9 | 2018 | 1722 | 0.460 |
Why?
|
| DNA Copy Number Variations | 13 | 2021 | 2046 | 0.450 |
Why?
|
| Zebrafish | 21 | 2018 | 3037 | 0.440 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 11 | 2023 | 494 | 0.440 |
Why?
|
| Burkitt Lymphoma | 6 | 2016 | 337 | 0.440 |
Why?
|
| Stem Cell Transplantation | 8 | 2021 | 1601 | 0.440 |
Why?
|
| Genomic Instability | 5 | 2021 | 715 | 0.430 |
Why?
|
| Progeria | 5 | 2013 | 188 | 0.430 |
Why?
|
| Treatment Outcome | 116 | 2024 | 65365 | 0.430 |
Why?
|
| Aged, 80 and over | 97 | 2024 | 59683 | 0.430 |
Why?
|
| Receptors, Antigen, B-Cell | 8 | 2023 | 547 | 0.430 |
Why?
|
| Thrombosis | 8 | 2023 | 2955 | 0.430 |
Why?
|
| Lymphocyte Transfusion | 8 | 2021 | 232 | 0.420 |
Why?
|
| In Situ Hybridization, Fluorescence | 11 | 2016 | 2524 | 0.420 |
Why?
|
| Leukemia, Myeloid | 8 | 2021 | 693 | 0.420 |
Why?
|
| Enoxaparin | 5 | 2020 | 391 | 0.410 |
Why?
|
| Adolescent | 115 | 2024 | 89182 | 0.400 |
Why?
|
| Survival Analysis | 47 | 2020 | 10117 | 0.400 |
Why?
|
| Lymphopenia | 3 | 2019 | 298 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 9 | 6 | 2020 | 534 | 0.400 |
Why?
|
| Transplantation, Autologous | 34 | 2020 | 2127 | 0.400 |
Why?
|
| Child, Preschool | 79 | 2024 | 42654 | 0.390 |
Why?
|
| DNA, Mitochondrial | 3 | 2024 | 871 | 0.390 |
Why?
|
| Aminoglycosides | 1 | 2012 | 159 | 0.390 |
Why?
|
| Melanoma | 15 | 2022 | 5705 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 13 | 2024 | 1408 | 0.380 |
Why?
|
| Cell Line, Tumor | 34 | 2024 | 17132 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 15 | 2018 | 2846 | 0.380 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2013 | 171 | 0.380 |
Why?
|
| Bone Marrow | 15 | 2022 | 2929 | 0.370 |
Why?
|
| Ikaros Transcription Factor | 4 | 2021 | 233 | 0.360 |
Why?
|
| Janus Kinase 2 | 6 | 2024 | 561 | 0.360 |
Why?
|
| Child | 99 | 2024 | 80894 | 0.360 |
Why?
|
| Anthracyclines | 3 | 2023 | 286 | 0.350 |
Why?
|
| Reed-Sternberg Cells | 4 | 2018 | 78 | 0.350 |
Why?
|
| Leukemia, Promyelocytic, Acute | 5 | 2013 | 248 | 0.350 |
Why?
|
| Intracranial Hemorrhages | 5 | 2023 | 811 | 0.350 |
Why?
|
| Hematopoietic Stem Cells | 16 | 2021 | 3407 | 0.350 |
Why?
|
| Chromosome Deletion | 8 | 2020 | 1390 | 0.340 |
Why?
|
| Neuroblastoma | 7 | 2017 | 1265 | 0.340 |
Why?
|
| Disease Progression | 31 | 2020 | 13646 | 0.330 |
Why?
|
| Aging | 6 | 2023 | 8764 | 0.330 |
Why?
|
| Polyethylene Glycols | 6 | 2021 | 1195 | 0.330 |
Why?
|
| Protein Disulfide-Isomerases | 3 | 2019 | 210 | 0.330 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2019 | 2433 | 0.320 |
Why?
|
| Genes, p53 | 7 | 2017 | 715 | 0.320 |
Why?
|
| Transplantation Conditioning | 11 | 2022 | 1600 | 0.320 |
Why?
|
| Razoxane | 5 | 2012 | 43 | 0.320 |
Why?
|
| DNA Methylation | 15 | 2024 | 4419 | 0.320 |
Why?
|
| Mediastinal Neoplasms | 4 | 2019 | 403 | 0.320 |
Why?
|
| Evolution, Molecular | 6 | 2021 | 1893 | 0.310 |
Why?
|
| Blood Donors | 3 | 2019 | 344 | 0.310 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 3 | 2020 | 103 | 0.310 |
Why?
|
| Mice | 64 | 2024 | 82004 | 0.310 |
Why?
|
| Young Adult | 56 | 2024 | 60048 | 0.300 |
Why?
|
| Tumor Microenvironment | 8 | 2022 | 3940 | 0.300 |
Why?
|
| Signal Transduction | 30 | 2024 | 23629 | 0.300 |
Why?
|
| Pyrazoles | 8 | 2019 | 2021 | 0.300 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 5 | 2007 | 167 | 0.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 15 | 2022 | 5422 | 0.290 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 2024 | 706 | 0.290 |
Why?
|
| Animals | 91 | 2024 | 169322 | 0.290 |
Why?
|
| Follow-Up Studies | 55 | 2023 | 39405 | 0.290 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 6 | 2017 | 355 | 0.290 |
Why?
|
| Quercetin | 2 | 2019 | 96 | 0.290 |
Why?
|
| Phosphoproteins | 5 | 2020 | 2448 | 0.290 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 2 | 2018 | 43 | 0.290 |
Why?
|
| Etoposide | 11 | 2019 | 639 | 0.280 |
Why?
|
| PTEN Phosphohydrolase | 7 | 2020 | 1118 | 0.280 |
Why?
|
| Lung Neoplasms | 22 | 2022 | 13576 | 0.280 |
Why?
|
| Gene Deletion | 7 | 2020 | 2673 | 0.280 |
Why?
|
| Recurrence | 33 | 2023 | 8501 | 0.280 |
Why?
|
| Drug Administration Schedule | 26 | 2019 | 4859 | 0.280 |
Why?
|
| Dexamethasone | 7 | 2018 | 1965 | 0.280 |
Why?
|
| Immunoglobulin Heavy Chains | 11 | 2018 | 648 | 0.270 |
Why?
|
| Cell Proliferation | 20 | 2021 | 10464 | 0.270 |
Why?
|
| Antigens, CD | 16 | 2011 | 4031 | 0.270 |
Why?
|
| Infant | 52 | 2021 | 36512 | 0.270 |
Why?
|
| Nuclear Proteins | 10 | 2024 | 5802 | 0.270 |
Why?
|
| Clone Cells | 11 | 2021 | 1671 | 0.270 |
Why?
|
| Chromosomes, Human | 3 | 2016 | 444 | 0.270 |
Why?
|
| Atherosclerosis | 2 | 2019 | 3431 | 0.260 |
Why?
|
| Polymerase Chain Reaction | 26 | 2016 | 6084 | 0.260 |
Why?
|
| Azepines | 2 | 2019 | 329 | 0.260 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2024 | 954 | 0.260 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 3 | 2018 | 168 | 0.260 |
Why?
|
| Combined Modality Therapy | 39 | 2020 | 8562 | 0.260 |
Why?
|
| Brain Ischemia | 1 | 2019 | 3008 | 0.260 |
Why?
|
| Thrombocytopenia | 5 | 2023 | 1180 | 0.260 |
Why?
|
| Mitochondria | 9 | 2024 | 3675 | 0.260 |
Why?
|
| DNA, Neoplasm | 6 | 2020 | 1748 | 0.260 |
Why?
|
| Heparin, Low-Molecular-Weight | 4 | 2022 | 344 | 0.260 |
Why?
|
| Apoptosis Regulatory Proteins | 5 | 2014 | 1151 | 0.260 |
Why?
|
| Immunoglobulins | 5 | 2018 | 855 | 0.260 |
Why?
|
| Genetic Linkage | 3 | 2005 | 2342 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 18 | 2021 | 16027 | 0.250 |
Why?
|
| Antigen Presentation | 6 | 2023 | 1251 | 0.250 |
Why?
|
| Chemokine CCL3 | 3 | 2016 | 85 | 0.250 |
Why?
|
| High-Throughput Nucleotide Sequencing | 9 | 2024 | 3666 | 0.250 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2023 | 2884 | 0.250 |
Why?
|
| Neoplasm Staging | 31 | 2019 | 11254 | 0.250 |
Why?
|
| Retrospective Studies | 61 | 2024 | 81768 | 0.250 |
Why?
|
| Natural Killer T-Cells | 3 | 2013 | 318 | 0.250 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 2295 | 0.250 |
Why?
|
| Transcription, Genetic | 9 | 2021 | 7599 | 0.250 |
Why?
|
| Adenosine A2 Receptor Agonists | 3 | 2019 | 31 | 0.250 |
Why?
|
| Whole-Body Irradiation | 8 | 2007 | 435 | 0.240 |
Why?
|
| Receptor, Notch1 | 4 | 2014 | 520 | 0.240 |
Why?
|
| Myeloid Cells | 6 | 2018 | 832 | 0.240 |
Why?
|
| Piperidines | 8 | 2022 | 1660 | 0.240 |
Why?
|
| Epigenesis, Genetic | 7 | 2022 | 3826 | 0.240 |
Why?
|
| Cardiotonic Agents | 5 | 2016 | 544 | 0.240 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2016 | 646 | 0.240 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2018 | 555 | 0.240 |
Why?
|
| Alternative Splicing | 4 | 2019 | 1093 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2024 | 3616 | 0.230 |
Why?
|
| Tumor Cells, Cultured | 16 | 2022 | 6132 | 0.230 |
Why?
|
| Immunologic Memory | 5 | 2021 | 1374 | 0.230 |
Why?
|
| Immunoglobulin Variable Region | 7 | 2022 | 420 | 0.230 |
Why?
|
| Glutarates | 2 | 2018 | 243 | 0.230 |
Why?
|
| Dendritic Cells | 8 | 2024 | 2749 | 0.230 |
Why?
|
| Biological Assay | 1 | 2007 | 627 | 0.230 |
Why?
|
| Germ-Line Mutation | 7 | 2018 | 1885 | 0.230 |
Why?
|
| Survivors | 8 | 2016 | 2382 | 0.230 |
Why?
|
| Melanoma, Experimental | 4 | 2020 | 559 | 0.230 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2024 | 2568 | 0.230 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2024 | 41 | 0.230 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2012 | 529 | 0.220 |
Why?
|
| Immunohistochemistry | 18 | 2016 | 11117 | 0.220 |
Why?
|
| Hedgehog Proteins | 2 | 2019 | 770 | 0.220 |
Why?
|
| Translocation, Genetic | 13 | 2016 | 1395 | 0.220 |
Why?
|
| Lipopeptides | 1 | 2024 | 71 | 0.220 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 7 | 2004 | 631 | 0.220 |
Why?
|
| Fusion Proteins, bcr-abl | 8 | 2014 | 424 | 0.220 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 17 | 2014 | 3794 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 8 | 2012 | 1628 | 0.220 |
Why?
|
| Erythropoiesis | 3 | 2020 | 693 | 0.220 |
Why?
|
| Germinal Center | 2 | 2020 | 380 | 0.220 |
Why?
|
| p21-Activated Kinases | 1 | 2024 | 127 | 0.220 |
Why?
|
| Antigens, CD34 | 7 | 2013 | 656 | 0.220 |
Why?
|
| Antineoplastic Agents, Alkylating | 5 | 2014 | 618 | 0.210 |
Why?
|
| Cardiotoxins | 2 | 2013 | 36 | 0.210 |
Why?
|
| Cytidine Deaminase | 2 | 2015 | 243 | 0.210 |
Why?
|
| Pyridines | 5 | 2019 | 2889 | 0.210 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 3 | 2016 | 129 | 0.210 |
Why?
|
| Single-Cell Analysis | 5 | 2024 | 2533 | 0.210 |
Why?
|
| Vaccination | 5 | 2024 | 3431 | 0.210 |
Why?
|
| Mice, Inbred NOD | 9 | 2021 | 1839 | 0.210 |
Why?
|
| Hydroxyurea | 2 | 2022 | 284 | 0.210 |
Why?
|
| Lymphocyte Activation | 8 | 2021 | 5496 | 0.210 |
Why?
|
| Receptor, Adenosine A2A | 2 | 2013 | 129 | 0.210 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2019 | 458 | 0.200 |
Why?
|
| HLA Antigens | 5 | 2022 | 1337 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2023 | 5707 | 0.200 |
Why?
|
| Peptides | 4 | 2020 | 4352 | 0.200 |
Why?
|
| Antibodies, Neoplasm | 3 | 2010 | 283 | 0.200 |
Why?
|
| Treatment Failure | 12 | 2014 | 2664 | 0.200 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 617 | 0.200 |
Why?
|
| DNA Mutational Analysis | 13 | 2020 | 4120 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2014 | 2461 | 0.200 |
Why?
|
| Neutropenia | 5 | 2023 | 893 | 0.200 |
Why?
|
| Zebrafish Proteins | 3 | 2018 | 1019 | 0.200 |
Why?
|
| Alleles | 17 | 2020 | 6892 | 0.200 |
Why?
|
| Graft vs Leukemia Effect | 4 | 2020 | 121 | 0.200 |
Why?
|
| Lymphocyte Depletion | 7 | 2004 | 605 | 0.200 |
Why?
|
| Immunotherapy | 8 | 2023 | 4740 | 0.200 |
Why?
|
| Cardiovascular Agents | 2 | 2023 | 849 | 0.200 |
Why?
|
| Risk Factors | 48 | 2024 | 74954 | 0.190 |
Why?
|
| Genes, myc | 6 | 2015 | 391 | 0.190 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 2020 | 1438 | 0.190 |
Why?
|
| Sequence Deletion | 4 | 2018 | 1496 | 0.190 |
Why?
|
| Genomics | 7 | 2022 | 5916 | 0.190 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2023 | 2763 | 0.190 |
Why?
|
| Immunosuppressive Agents | 2 | 2013 | 4209 | 0.190 |
Why?
|
| Purines | 3 | 2019 | 615 | 0.190 |
Why?
|
| Dacarbazine | 3 | 2019 | 560 | 0.190 |
Why?
|
| Histone-Lysine N-Methyltransferase | 6 | 2020 | 697 | 0.190 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2022 | 187 | 0.190 |
Why?
|
| Piperazines | 9 | 2016 | 2552 | 0.190 |
Why?
|
| Models, Biological | 8 | 2020 | 9494 | 0.190 |
Why?
|
| Time Factors | 42 | 2019 | 40267 | 0.190 |
Why?
|
| Gene Duplication | 3 | 2014 | 315 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 17 | 2015 | 4584 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2018 | 6541 | 0.190 |
Why?
|
| Telomerase | 2 | 2021 | 752 | 0.190 |
Why?
|
| Antigens, Differentiation | 5 | 2010 | 921 | 0.180 |
Why?
|
| Brain Neoplasms | 5 | 2023 | 9197 | 0.180 |
Why?
|
| Base Sequence | 12 | 2020 | 12421 | 0.180 |
Why?
|
| Antigen-Presenting Cells | 6 | 2023 | 962 | 0.180 |
Why?
|
| Up-Regulation | 10 | 2019 | 4137 | 0.180 |
Why?
|
| Genotype | 21 | 2024 | 13038 | 0.180 |
Why?
|
| Heart Diseases | 3 | 2023 | 2819 | 0.180 |
Why?
|
| Histiocytes | 1 | 2021 | 97 | 0.180 |
Why?
|
| Gene Expression Regulation | 10 | 2023 | 11914 | 0.180 |
Why?
|
| Adenocarcinoma | 9 | 2017 | 6404 | 0.180 |
Why?
|
| Bone Marrow Cells | 12 | 2013 | 2414 | 0.180 |
Why?
|
| Enzyme Inhibitors | 7 | 2014 | 3722 | 0.180 |
Why?
|
| Blood Group Antigens | 1 | 2022 | 185 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 293 | 0.180 |
Why?
|
| Prospective Studies | 38 | 2024 | 54921 | 0.180 |
Why?
|
| Paclitaxel | 9 | 2022 | 1736 | 0.180 |
Why?
|
| Haploinsufficiency | 2 | 2013 | 336 | 0.180 |
Why?
|
| Cell Cycle Proteins | 8 | 2018 | 3457 | 0.180 |
Why?
|
| Sequence Analysis, DNA | 11 | 2018 | 4774 | 0.170 |
Why?
|
| Membrane Proteins | 5 | 2019 | 7885 | 0.170 |
Why?
|
| Selection, Genetic | 3 | 2020 | 877 | 0.170 |
Why?
|
| Polyomavirus Infections | 1 | 2022 | 192 | 0.170 |
Why?
|
| Precancerous Conditions | 3 | 2014 | 984 | 0.170 |
Why?
|
| Multiple Myeloma | 7 | 2020 | 5192 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2019 | 10776 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 16 | 2018 | 9261 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 9 | 2014 | 1614 | 0.170 |
Why?
|
| Peyer's Patches | 1 | 2020 | 120 | 0.170 |
Why?
|
| Endometrial Neoplasms | 4 | 2014 | 1382 | 0.170 |
Why?
|
| Galectin 1 | 2 | 2013 | 128 | 0.170 |
Why?
|
| Staurosporine | 4 | 2004 | 241 | 0.170 |
Why?
|
| Mutation, Missense | 4 | 2019 | 2593 | 0.170 |
Why?
|
| Skin Neoplasms | 5 | 2022 | 5857 | 0.170 |
Why?
|
| Phenotype | 18 | 2024 | 16716 | 0.170 |
Why?
|
| Restless Legs Syndrome | 1 | 2022 | 235 | 0.160 |
Why?
|
| Thromboplastin | 2 | 2012 | 288 | 0.160 |
Why?
|
| Azacitidine | 5 | 2024 | 335 | 0.160 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2001 | 540 | 0.160 |
Why?
|
| Flow Cytometry | 15 | 2015 | 5898 | 0.160 |
Why?
|
| Antibody Affinity | 1 | 2020 | 253 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2014 | 957 | 0.160 |
Why?
|
| Thrombocythemia, Essential | 1 | 2020 | 114 | 0.160 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2012 | 238 | 0.160 |
Why?
|
| SEER Program | 5 | 2017 | 1474 | 0.160 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 5 | 2015 | 69 | 0.160 |
Why?
|
| beta 2-Microglobulin | 2 | 2018 | 329 | 0.160 |
Why?
|
| Receptors, Notch | 2 | 2021 | 749 | 0.160 |
Why?
|
| Gene Expression | 10 | 2022 | 7595 | 0.160 |
Why?
|
| Chemokine CCL4 | 2 | 2016 | 127 | 0.160 |
Why?
|
| Radioactive Pollutants | 1 | 2018 | 13 | 0.160 |
Why?
|
| Substrate Specificity | 2 | 2021 | 1758 | 0.160 |
Why?
|
| Administration, Oral | 11 | 2022 | 4043 | 0.160 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2018 | 15 | 0.160 |
Why?
|
| Lysine | 2 | 2014 | 988 | 0.160 |
Why?
|
| Melanoma-Specific Antigens | 3 | 2018 | 73 | 0.160 |
Why?
|
| Repressor Proteins | 5 | 2018 | 2986 | 0.160 |
Why?
|
| Cytophotometry | 1 | 2018 | 8 | 0.160 |
Why?
|
| Karyotyping | 9 | 2019 | 1173 | 0.160 |
Why?
|
| Drug Discovery | 2 | 2017 | 1067 | 0.160 |
Why?
|
| Mycoses | 1 | 2022 | 386 | 0.160 |
Why?
|
| Incidence | 20 | 2024 | 21544 | 0.160 |
Why?
|
| Breast Neoplasms | 19 | 2023 | 21163 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2021 | 1855 | 0.160 |
Why?
|
| Toll-Like Receptors | 2 | 2013 | 582 | 0.160 |
Why?
|
| Transcription Factor AP-1 | 2 | 2012 | 321 | 0.150 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 737 | 0.150 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2020 | 182 | 0.150 |
Why?
|
| Transcription Factors | 12 | 2021 | 12166 | 0.150 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2018 | 89 | 0.150 |
Why?
|
| Cohort Studies | 29 | 2024 | 41791 | 0.150 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 4 | 2018 | 308 | 0.150 |
Why?
|
| Ifosfamide | 4 | 2014 | 234 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2024 | 3728 | 0.150 |
Why?
|
| Trans-Activators | 5 | 2013 | 2855 | 0.150 |
Why?
|
| Epoxy Compounds | 1 | 2018 | 137 | 0.150 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 373 | 0.150 |
Why?
|
| Genome, Human | 5 | 2021 | 4450 | 0.150 |
Why?
|
| Hematology | 1 | 2021 | 244 | 0.150 |
Why?
|
| Animals, Genetically Modified | 9 | 2017 | 1563 | 0.150 |
Why?
|
| Tumor Escape | 1 | 2021 | 372 | 0.150 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 749 | 0.150 |
Why?
|
| Case-Control Studies | 23 | 2018 | 22292 | 0.150 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2022 | 330 | 0.150 |
Why?
|
| Event-Related Potentials, P300 | 1 | 1999 | 149 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 6 | 2019 | 890 | 0.150 |
Why?
|
| Alcoholism | 2 | 1999 | 1981 | 0.150 |
Why?
|
| Fusobacterium | 1 | 2017 | 56 | 0.150 |
Why?
|
| Proportional Hazards Models | 16 | 2017 | 12557 | 0.150 |
Why?
|
| Death, Sudden | 1 | 2019 | 301 | 0.150 |
Why?
|
| Immunity, Innate | 6 | 2013 | 3079 | 0.140 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2018 | 163 | 0.140 |
Why?
|
| Glutathione Transferase | 3 | 2004 | 564 | 0.140 |
Why?
|
| Homeodomain Proteins | 6 | 2013 | 2429 | 0.140 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2016 | 1362 | 0.140 |
Why?
|
| Immunophenotyping | 12 | 2016 | 1866 | 0.140 |
Why?
|
| Thalidomide | 5 | 2016 | 886 | 0.140 |
Why?
|
| K562 Cells | 7 | 2019 | 637 | 0.140 |
Why?
|
| Macrolides | 1 | 2018 | 205 | 0.140 |
Why?
|
| Aspartate-Ammonia Ligase | 2 | 2014 | 18 | 0.140 |
Why?
|
| Infusions, Intravenous | 12 | 2015 | 2226 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2018 | 354 | 0.140 |
Why?
|
| Stroke | 1 | 2019 | 9742 | 0.140 |
Why?
|
| Premedication | 1 | 2018 | 246 | 0.140 |
Why?
|
| Histone Code | 1 | 2018 | 160 | 0.140 |
Why?
|
| CpG Islands | 5 | 2024 | 1208 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2013 | 1064 | 0.140 |
Why?
|
| Linear Models | 1 | 2007 | 5878 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 3 | 2020 | 937 | 0.140 |
Why?
|
| Genetic Markers | 6 | 2012 | 2604 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 8 | 2020 | 2811 | 0.140 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2015 | 289 | 0.140 |
Why?
|
| Thymidylate Synthase | 1 | 2016 | 74 | 0.140 |
Why?
|
| Thromboembolism | 2 | 2014 | 1004 | 0.140 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2018 | 245 | 0.140 |
Why?
|
| Live Birth | 1 | 2020 | 516 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 1105 | 0.140 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2018 | 572 | 0.140 |
Why?
|
| Gene Frequency | 8 | 2020 | 3615 | 0.140 |
Why?
|
| Atovaquone | 1 | 2016 | 56 | 0.140 |
Why?
|
| CD40 Ligand | 2 | 2012 | 524 | 0.140 |
Why?
|
| Glioblastoma | 3 | 2023 | 3526 | 0.130 |
Why?
|
| Brain Stem Neoplasms | 1 | 2018 | 191 | 0.130 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2016 | 10 | 0.130 |
Why?
|
| Multivariate Analysis | 13 | 2018 | 12092 | 0.130 |
Why?
|
| Histocompatibility Testing | 5 | 2023 | 716 | 0.130 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 755 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myb | 2 | 2007 | 82 | 0.130 |
Why?
|
| Mitoxantrone | 4 | 2019 | 148 | 0.130 |
Why?
|
| STAT1 Transcription Factor | 4 | 2013 | 343 | 0.130 |
Why?
|
| Metronidazole | 1 | 2017 | 233 | 0.130 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2014 | 276 | 0.130 |
Why?
|
| DNA Damage | 6 | 2021 | 2459 | 0.130 |
Why?
|
| Hydroxamic Acids | 2 | 2018 | 482 | 0.130 |
Why?
|
| Spliceosomes | 2 | 2018 | 116 | 0.130 |
Why?
|
| Ribosomal Proteins | 3 | 2015 | 370 | 0.130 |
Why?
|
| Adenine | 6 | 2022 | 993 | 0.130 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2016 | 77 | 0.130 |
Why?
|
| Pituitary Neoplasms | 2 | 2018 | 1325 | 0.130 |
Why?
|
| RNA, Small Interfering | 5 | 2018 | 3436 | 0.130 |
Why?
|
| Microcirculation | 2 | 2019 | 1282 | 0.130 |
Why?
|
| Epitopes | 2 | 2021 | 2525 | 0.130 |
Why?
|
| Hydrocarbons | 1 | 2016 | 105 | 0.130 |
Why?
|
| Gene Dosage | 4 | 2018 | 1221 | 0.130 |
Why?
|
| Genetic Variation | 7 | 2021 | 6606 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2018 | 640 | 0.130 |
Why?
|
| Point Mutation | 4 | 2011 | 1595 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2015 | 1166 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 580 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2016 | 4069 | 0.130 |
Why?
|
| Cell Survival | 10 | 2018 | 5792 | 0.130 |
Why?
|
| Mice, Knockout | 11 | 2021 | 14481 | 0.130 |
Why?
|
| Killer Cells, Natural | 3 | 2020 | 2207 | 0.130 |
Why?
|
| Oncogenes | 2 | 2018 | 1234 | 0.130 |
Why?
|
| Symbiosis | 1 | 2018 | 297 | 0.120 |
Why?
|
| Oncogene Proteins | 3 | 2012 | 718 | 0.120 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 539 | 0.120 |
Why?
|
| Quinazolines | 3 | 2017 | 1374 | 0.120 |
Why?
|
| Idarubicin | 4 | 2019 | 59 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 387 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 2909 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
| Gout | 1 | 2022 | 621 | 0.120 |
Why?
|
| Glycogen Synthase | 1 | 2015 | 62 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 13 | 2024 | 22355 | 0.120 |
Why?
|
| Genome | 3 | 2011 | 1747 | 0.120 |
Why?
|
| Receptors, Calcitriol | 2 | 2008 | 361 | 0.120 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2015 | 105 | 0.120 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2015 | 44 | 0.120 |
Why?
|
| Platelet Count | 4 | 2020 | 784 | 0.120 |
Why?
|
| Immunoconjugates | 2 | 2019 | 969 | 0.120 |
Why?
|
| PPAR gamma | 1 | 2018 | 487 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2018 | 356 | 0.120 |
Why?
|
| NF-kappa B | 7 | 2021 | 2487 | 0.120 |
Why?
|
| Gene Regulatory Networks | 2 | 2021 | 1753 | 0.120 |
Why?
|
| Warfarin | 3 | 2022 | 1493 | 0.120 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 2 | 2020 | 58 | 0.120 |
Why?
|
| Glucocorticoids | 3 | 2020 | 2168 | 0.120 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2006 | 263 | 0.120 |
Why?
|
| Recombinant Proteins | 11 | 2012 | 6512 | 0.120 |
Why?
|
| Antigens, CD19 | 4 | 2024 | 437 | 0.120 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2014 | 17 | 0.120 |
Why?
|
| Citric Acid Cycle | 1 | 2016 | 234 | 0.120 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 1232 | 0.120 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2010 | 474 | 0.120 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 72 | 0.120 |
Why?
|
| Megakaryocytes | 2 | 2018 | 571 | 0.120 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 366 | 0.120 |
Why?
|
| Anilides | 1 | 2017 | 414 | 0.120 |
Why?
|
| Telomere | 1 | 2020 | 943 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2020 | 2066 | 0.120 |
Why?
|
| Age Factors | 17 | 2018 | 18472 | 0.120 |
Why?
|
| Mitochondria, Heart | 1 | 2016 | 236 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 10 | 2018 | 5800 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 2 | 2016 | 875 | 0.120 |
Why?
|
| Core Binding Factors | 1 | 2014 | 29 | 0.120 |
Why?
|
| Glycogen | 1 | 2015 | 252 | 0.120 |
Why?
|
| Retinoblastoma Protein | 1 | 2018 | 673 | 0.120 |
Why?
|
| HMGN1 Protein | 1 | 2014 | 27 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2016 | 2044 | 0.120 |
Why?
|
| Glioma | 3 | 2018 | 3526 | 0.120 |
Why?
|
| Sarcoma, Myeloid | 1 | 2014 | 52 | 0.110 |
Why?
|
| Cell Differentiation | 15 | 2017 | 11659 | 0.110 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2016 | 615 | 0.110 |
Why?
|
| Thrombin | 1 | 2017 | 600 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 3 | 2016 | 1492 | 0.110 |
Why?
|
| Interleukin-11 | 2 | 2006 | 59 | 0.110 |
Why?
|
| Tretinoin | 2 | 2013 | 524 | 0.110 |
Why?
|
| Acyltransferases | 1 | 2016 | 306 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2018 | 1368 | 0.110 |
Why?
|
| Mice, Transgenic | 9 | 2019 | 9563 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 3 | 2014 | 1356 | 0.110 |
Why?
|
| Neoplasm Transplantation | 5 | 2018 | 2017 | 0.110 |
Why?
|
| Disease Models, Animal | 10 | 2021 | 18358 | 0.110 |
Why?
|
| Loss of Heterozygosity | 5 | 2020 | 663 | 0.110 |
Why?
|
| Interleukin-3 | 4 | 2011 | 425 | 0.110 |
Why?
|
| Amifostine | 2 | 2004 | 40 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2013 | 21 | 0.110 |
Why?
|
| Interleukin-1alpha | 1 | 2014 | 86 | 0.110 |
Why?
|
| Transplantation Chimera | 4 | 2014 | 594 | 0.110 |
Why?
|
| Cell Line | 12 | 2024 | 15593 | 0.110 |
Why?
|
| Cell Cycle | 6 | 2012 | 2934 | 0.110 |
Why?
|
| DNA | 4 | 2024 | 7211 | 0.110 |
Why?
|
| Siblings | 4 | 2015 | 829 | 0.110 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 2 | 2012 | 84 | 0.110 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 266 | 0.110 |
Why?
|
| Phosphorylation | 9 | 2024 | 8326 | 0.110 |
Why?
|
| TYK2 Kinase | 1 | 2013 | 38 | 0.110 |
Why?
|
| Radiation-Protective Agents | 2 | 2004 | 88 | 0.110 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 34 | 0.110 |
Why?
|
| Histones | 2 | 2014 | 2593 | 0.110 |
Why?
|
| Interferon-gamma | 8 | 2023 | 3164 | 0.110 |
Why?
|
| Nanowires | 1 | 2012 | 31 | 0.110 |
Why?
|
| DNA Primers | 6 | 2014 | 2823 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 110 | 0.100 |
Why?
|
| Mice, SCID | 5 | 2021 | 2632 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2014 | 930 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 125 | 0.100 |
Why?
|
| Aspirin | 2 | 2023 | 3136 | 0.100 |
Why?
|
| Farnesyltranstransferase | 1 | 2012 | 71 | 0.100 |
Why?
|
| Bone Marrow Purging | 6 | 2007 | 108 | 0.100 |
Why?
|
| Fatigue | 4 | 2023 | 1555 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 4 | 2013 | 2635 | 0.100 |
Why?
|
| Cytogenetics | 2 | 2010 | 198 | 0.100 |
Why?
|
| Gallium | 2 | 2004 | 30 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2015 | 706 | 0.100 |
Why?
|
| Down Syndrome | 3 | 2018 | 915 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2018 | 3111 | 0.100 |
Why?
|
| Silicon | 1 | 2012 | 143 | 0.100 |
Why?
|
| Jurkat Cells | 4 | 2019 | 738 | 0.100 |
Why?
|
| Blood | 1 | 2014 | 597 | 0.100 |
Why?
|
| Carmustine | 1 | 2012 | 137 | 0.100 |
Why?
|
| Blood Platelets | 3 | 2019 | 2476 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 2830 | 0.100 |
Why?
|
| Indoles | 4 | 2018 | 1825 | 0.100 |
Why?
|
| Cell Movement | 8 | 2018 | 5214 | 0.100 |
Why?
|
| Coagulants | 1 | 2012 | 45 | 0.100 |
Why?
|
| Activating Transcription Factors | 1 | 2011 | 30 | 0.100 |
Why?
|
| Ferritins | 1 | 2015 | 601 | 0.100 |
Why?
|
| Hemochromatosis | 1 | 2013 | 176 | 0.100 |
Why?
|
| Endonucleases | 2 | 2005 | 371 | 0.100 |
Why?
|
| Molecular Sequence Data | 13 | 2014 | 17626 | 0.100 |
Why?
|
| Oxidative Phosphorylation | 3 | 2024 | 501 | 0.100 |
Why?
|
| Cells, Cultured | 11 | 2018 | 19019 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2020 | 876 | 0.100 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2012 | 100 | 0.100 |
Why?
|
| Membrane Glycoproteins | 4 | 2008 | 3712 | 0.100 |
Why?
|
| Genes, Immunoglobulin | 4 | 2011 | 286 | 0.100 |
Why?
|
| Ventricular Function, Left | 5 | 2023 | 3942 | 0.100 |
Why?
|
| Risk Assessment | 11 | 2020 | 24316 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 1597 | 0.090 |
Why?
|
| Mutagenesis, Insertional | 2 | 2018 | 662 | 0.090 |
Why?
|
| Genes, ras | 3 | 2007 | 665 | 0.090 |
Why?
|
| Computational Biology | 2 | 2021 | 3541 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 598 | 0.090 |
Why?
|
| Glutathione S-Transferase pi | 3 | 2006 | 99 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 7458 | 0.090 |
Why?
|
| Endometrium | 1 | 2014 | 407 | 0.090 |
Why?
|
| Factor VIIa | 1 | 2012 | 103 | 0.090 |
Why?
|
| Quality of Life | 7 | 2023 | 13499 | 0.090 |
Why?
|
| Chromosome Breakage | 1 | 2011 | 159 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2021 | 2474 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2014 | 827 | 0.090 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2009 | 199 | 0.090 |
Why?
|
| Sex Factors | 4 | 2020 | 10656 | 0.090 |
Why?
|
| Bone and Bones | 2 | 2012 | 2588 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2022 | 1756 | 0.090 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2015 | 271 | 0.090 |
Why?
|
| Kidney Neoplasms | 3 | 2020 | 4301 | 0.090 |
Why?
|
| Erythroid Cells | 2 | 2013 | 238 | 0.090 |
Why?
|
| Cardiomyopathies | 3 | 2012 | 2056 | 0.090 |
Why?
|
| Monitoring, Immunologic | 2 | 2021 | 100 | 0.090 |
Why?
|
| YY1 Transcription Factor | 1 | 2011 | 60 | 0.090 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 2010 | 16 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 58 | 0.090 |
Why?
|
| Protein Kinase C | 2 | 2007 | 1207 | 0.090 |
Why?
|
| Bacteremia | 1 | 2018 | 985 | 0.090 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 101 | 0.090 |
Why?
|
| Chromosome Mapping | 3 | 2013 | 4622 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2019 | 18047 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2015 | 620 | 0.090 |
Why?
|
| Thyroid Neoplasms | 3 | 2018 | 2360 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 1111 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 3 | 2012 | 323 | 0.090 |
Why?
|
| Neutrophils | 2 | 2023 | 3785 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 21 | 3 | 2014 | 229 | 0.090 |
Why?
|
| Gene Rearrangement | 5 | 2018 | 1139 | 0.090 |
Why?
|
| STAT Transcription Factors | 2 | 2023 | 189 | 0.090 |
Why?
|
| Blotting, Western | 7 | 2013 | 5033 | 0.090 |
Why?
|
| Myocardial Stunning | 1 | 2010 | 67 | 0.090 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2010 | 81 | 0.090 |
Why?
|
| Philadelphia Chromosome | 4 | 2022 | 119 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2016 | 362 | 0.090 |
Why?
|
| beta-Galactosidase | 2 | 2008 | 574 | 0.090 |
Why?
|
| HIV Antibodies | 1 | 2017 | 1341 | 0.090 |
Why?
|
| PAX2 Transcription Factor | 1 | 2010 | 86 | 0.090 |
Why?
|
| Erwinia | 1 | 2010 | 22 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 3199 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 2 | 2014 | 1622 | 0.090 |
Why?
|
| Vitamin D | 4 | 2008 | 3311 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2010 | 192 | 0.090 |
Why?
|
| Neoplasm Metastasis | 13 | 2017 | 4921 | 0.090 |
Why?
|
| Linkage Disequilibrium | 4 | 2011 | 1998 | 0.090 |
Why?
|
| Leukocyte Count | 4 | 2023 | 1605 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 775 | 0.090 |
Why?
|
| Daunorubicin | 2 | 2024 | 157 | 0.090 |
Why?
|
| Boronic Acids | 4 | 2013 | 915 | 0.090 |
Why?
|
| Feasibility Studies | 8 | 2019 | 5311 | 0.090 |
Why?
|
| Predictive Value of Tests | 16 | 2020 | 15455 | 0.090 |
Why?
|
| Janus Kinases | 2 | 2023 | 253 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2013 | 2060 | 0.090 |
Why?
|
| Lymphocytes | 3 | 2012 | 2610 | 0.090 |
Why?
|
| DNA Repair | 3 | 2021 | 2050 | 0.080 |
Why?
|
| Fractures, Bone | 3 | 2017 | 2062 | 0.080 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 4908 | 0.080 |
Why?
|
| Interleukin-2 | 4 | 2011 | 1894 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2017 | 1152 | 0.080 |
Why?
|
| Troponin T | 2 | 2012 | 787 | 0.080 |
Why?
|
| Sirolimus | 3 | 2012 | 1542 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2007 | 1122 | 0.080 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2010 | 123 | 0.080 |
Why?
|
| Interferon-alpha | 4 | 2022 | 910 | 0.080 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 525 | 0.080 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2011 | 173 | 0.080 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 199 | 0.080 |
Why?
|
| Inheritance Patterns | 1 | 2012 | 344 | 0.080 |
Why?
|
| Teratoma | 1 | 2012 | 405 | 0.080 |
Why?
|
| Codon, Terminator | 1 | 2010 | 125 | 0.080 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2011 | 241 | 0.080 |
Why?
|
| Integrins | 1 | 2014 | 843 | 0.080 |
Why?
|
| Antigens, Surface | 3 | 2010 | 1616 | 0.080 |
Why?
|
| Fibroblasts | 2 | 2018 | 4175 | 0.080 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2009 | 133 | 0.080 |
Why?
|
| Uniparental Disomy | 1 | 2009 | 46 | 0.080 |
Why?
|
| Cisplatin | 7 | 2014 | 1661 | 0.080 |
Why?
|
| Gene Library | 5 | 2011 | 1061 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 1 | 2011 | 513 | 0.080 |
Why?
|
| Haplotypes | 5 | 2019 | 2724 | 0.080 |
Why?
|
| Acute Disease | 10 | 2019 | 7242 | 0.080 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 2 | 2014 | 105 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2006 | 827 | 0.080 |
Why?
|
| Receptors, IgE | 1 | 2010 | 375 | 0.080 |
Why?
|
| beta Catenin | 1 | 2014 | 1047 | 0.080 |
Why?
|
| Hematologic Diseases | 5 | 2006 | 499 | 0.080 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 1135 | 0.080 |
Why?
|
| Germ-Free Life | 2 | 2020 | 187 | 0.080 |
Why?
|
| Macrophages | 3 | 2020 | 5796 | 0.080 |
Why?
|
| Escherichia coli Proteins | 1 | 2015 | 1057 | 0.080 |
Why?
|
| Hemorrhage | 5 | 2023 | 3461 | 0.080 |
Why?
|
| Neural Crest | 1 | 2011 | 279 | 0.080 |
Why?
|
| Isoenzymes | 2 | 2003 | 1684 | 0.080 |
Why?
|
| Oxidative Stress | 4 | 2015 | 3139 | 0.080 |
Why?
|
| Genome-Wide Association Study | 5 | 2019 | 12775 | 0.080 |
Why?
|
| Leukemia, Experimental | 3 | 2016 | 225 | 0.080 |
Why?
|
| Echocardiography | 4 | 2018 | 5044 | 0.080 |
Why?
|
| Blast Crisis | 2 | 2006 | 102 | 0.080 |
Why?
|
| Interleukin-12 | 2 | 2003 | 577 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 7861 | 0.080 |
Why?
|
| Tissue Donors | 5 | 2024 | 2389 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2014 | 1795 | 0.080 |
Why?
|
| Immunoglobulin A | 1 | 2012 | 991 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2013 | 1536 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-rel | 2 | 2005 | 71 | 0.080 |
Why?
|
| Granzymes | 1 | 2010 | 278 | 0.080 |
Why?
|
| Carcinoma, Medullary | 2 | 1999 | 116 | 0.080 |
Why?
|
| Drug Therapy, Combination | 9 | 2011 | 6319 | 0.080 |
Why?
|
| Pyrazines | 4 | 2013 | 1206 | 0.080 |
Why?
|
| ras Proteins | 3 | 2024 | 1058 | 0.080 |
Why?
|
| Reproducibility of Results | 11 | 2019 | 20224 | 0.080 |
Why?
|
| Carcinoma | 3 | 2008 | 2340 | 0.080 |
Why?
|
| Behavior | 1 | 2011 | 543 | 0.080 |
Why?
|
| Benzoquinones | 1 | 2008 | 198 | 0.070 |
Why?
|
| Vaccines, Subunit | 1 | 2008 | 159 | 0.070 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 418 | 0.070 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 1292 | 0.070 |
Why?
|
| Gases | 1 | 2008 | 204 | 0.070 |
Why?
|
| Craniopharyngioma | 1 | 2010 | 279 | 0.070 |
Why?
|
| Insurance Coverage | 2 | 2017 | 1946 | 0.070 |
Why?
|
| Escherichia coli | 3 | 2015 | 4209 | 0.070 |
Why?
|
| Cranial Irradiation | 2 | 2007 | 395 | 0.070 |
Why?
|
| Gallium Radioisotopes | 2 | 2000 | 195 | 0.070 |
Why?
|
| Down-Regulation | 5 | 2017 | 2937 | 0.070 |
Why?
|
| Bleomycin | 4 | 2016 | 493 | 0.070 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2012 | 246 | 0.070 |
Why?
|
| Intrauterine Devices | 1 | 2009 | 117 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2019 | 6001 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 2411 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2015 | 3811 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2014 | 368 | 0.070 |
Why?
|
| Risk | 8 | 2017 | 9635 | 0.070 |
Why?
|
| Mutagenesis | 1 | 2011 | 1229 | 0.070 |
Why?
|
| MicroRNAs | 3 | 2014 | 3794 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1890 | 0.070 |
Why?
|
| Transgenes | 3 | 2018 | 1015 | 0.070 |
Why?
|
| Biopsy | 5 | 2018 | 6808 | 0.070 |
Why?
|
| Alu Elements | 1 | 2007 | 116 | 0.070 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 2006 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 1528 | 0.070 |
Why?
|
| Insurance, Health | 2 | 2017 | 2518 | 0.070 |
Why?
|
| Bacteria | 1 | 2018 | 2222 | 0.070 |
Why?
|
| United States | 14 | 2022 | 73144 | 0.070 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 319 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 3242 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 1133 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2009 | 725 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2021 | 5367 | 0.070 |
Why?
|
| Actins | 1 | 2014 | 2059 | 0.070 |
Why?
|
| Contraceptives, Oral | 1 | 2009 | 562 | 0.070 |
Why?
|
| Odds Ratio | 7 | 2022 | 9681 | 0.070 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2006 | 46 | 0.070 |
Why?
|
| Wilms Tumor | 2 | 2000 | 379 | 0.070 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2008 | 168 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2022 | 5443 | 0.070 |
Why?
|
| Pneumonia | 2 | 2012 | 2162 | 0.070 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2007 | 99 | 0.070 |
Why?
|
| Oxidants, Photochemical | 2 | 2004 | 77 | 0.070 |
Why?
|
| Cell Separation | 4 | 2009 | 1725 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 5 | 2010 | 286 | 0.070 |
Why?
|
| Heat-Shock Response | 1 | 2007 | 179 | 0.070 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 2 | 2007 | 111 | 0.070 |
Why?
|
| DNA Modification Methylases | 2 | 2018 | 209 | 0.060 |
Why?
|
| Coronavirus Infections | 1 | 2024 | 3118 | 0.060 |
Why?
|
| HEK293 Cells | 4 | 2018 | 4286 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 3 | 2010 | 1141 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2019 | 126 | 0.060 |
Why?
|
| RNA, Messenger | 10 | 2015 | 12801 | 0.060 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2008 | 249 | 0.060 |
Why?
|
| Genes, T-Cell Receptor beta | 2 | 2010 | 70 | 0.060 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 423 | 0.060 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2006 | 175 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 2004 | 767 | 0.060 |
Why?
|
| beta-Thalassemia | 1 | 2008 | 236 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2016 | 1473 | 0.060 |
Why?
|
| Mice, Mutant Strains | 3 | 2019 | 1755 | 0.060 |
Why?
|
| Benzamides | 6 | 2012 | 1380 | 0.060 |
Why?
|
| Biomimetics | 1 | 2007 | 172 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 588 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2005 | 29 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2008 | 619 | 0.060 |
Why?
|
| Metabolomics | 1 | 2015 | 1675 | 0.060 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 731 | 0.060 |
Why?
|
| Enzyme Activation | 4 | 2018 | 3585 | 0.060 |
Why?
|
| Positron-Emission Tomography | 3 | 2010 | 6670 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 2024 | 4570 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2011 | 878 | 0.060 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2007 | 236 | 0.060 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2005 | 67 | 0.060 |
Why?
|
| Telemedicine | 1 | 2023 | 3107 | 0.060 |
Why?
|
| Brassica | 1 | 2004 | 39 | 0.060 |
Why?
|
| Transaminases | 1 | 2006 | 199 | 0.060 |
Why?
|
| Heart Ventricles | 2 | 2019 | 3838 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 395 | 0.060 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 5168 | 0.060 |
Why?
|
| Brain Diseases | 1 | 2014 | 1552 | 0.060 |
Why?
|
| Blood Vessels | 1 | 2010 | 1110 | 0.060 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2004 | 50 | 0.060 |
Why?
|
| Herpesvirus 3, Human | 1 | 2006 | 159 | 0.060 |
Why?
|
| Isoquinolines | 2 | 2016 | 354 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2007 | 303 | 0.060 |
Why?
|
| Protein Array Analysis | 3 | 2012 | 399 | 0.060 |
Why?
|
| Cloning, Molecular | 4 | 2018 | 4168 | 0.060 |
Why?
|
| Morbidity | 2 | 2021 | 1758 | 0.060 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2005 | 133 | 0.060 |
Why?
|
| Cell Shape | 2 | 2016 | 371 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2013 | 1161 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2009 | 722 | 0.060 |
Why?
|
| Immunoglobulin Joining Region | 1 | 2004 | 37 | 0.060 |
Why?
|
| Proto-Oncogenes | 2 | 2003 | 322 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2022 | 3553 | 0.060 |
Why?
|
| RNA Interference | 4 | 2014 | 2836 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 4 | 2004 | 2923 | 0.060 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2010 | 843 | 0.060 |
Why?
|
| Chemokine CCL2 | 2 | 2009 | 606 | 0.060 |
Why?
|
| Nervous System Diseases | 2 | 2013 | 1664 | 0.060 |
Why?
|
| Tissue Preservation | 1 | 2004 | 173 | 0.060 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2024 | 36 | 0.060 |
Why?
|
| Metals | 1 | 2008 | 713 | 0.060 |
Why?
|
| Cytogenetic Analysis | 3 | 2011 | 270 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 246 | 0.060 |
Why?
|
| Proteins | 5 | 2017 | 6006 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2014 | 431 | 0.060 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2004 | 111 | 0.060 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2004 | 108 | 0.060 |
Why?
|
| Postpartum Hemorrhage | 1 | 2008 | 273 | 0.060 |
Why?
|
| Fluorouracil | 7 | 1999 | 1655 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 393 | 0.060 |
Why?
|
| Isoantibodies | 1 | 2008 | 682 | 0.060 |
Why?
|
| Dactinomycin | 1 | 2004 | 305 | 0.060 |
Why?
|
| Semen Preservation | 1 | 2003 | 35 | 0.060 |
Why?
|
| Protein Binding | 4 | 2018 | 9346 | 0.060 |
Why?
|
| Freezing | 1 | 2004 | 311 | 0.060 |
Why?
|
| Metaphase | 1 | 2003 | 145 | 0.060 |
Why?
|
| Mammography | 2 | 2013 | 2434 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2010 | 4357 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1727 | 0.050 |
Why?
|
| Protein Isoforms | 4 | 2013 | 1704 | 0.050 |
Why?
|
| Thiazoles | 1 | 2011 | 1542 | 0.050 |
Why?
|
| Body Mass Index | 3 | 2023 | 13050 | 0.050 |
Why?
|
| Salvage Therapy | 5 | 2010 | 1277 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2013 | 855 | 0.050 |
Why?
|
| Interphase | 1 | 2003 | 227 | 0.050 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2005 | 170 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 1998 | 622 | 0.050 |
Why?
|
| Herpes Zoster | 1 | 2006 | 252 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 1 | 2004 | 343 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2007 | 523 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2020 | 1320 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 1751 | 0.050 |
Why?
|
| Mast Cells | 1 | 2010 | 1407 | 0.050 |
Why?
|
| Retinal Vessels | 1 | 1989 | 864 | 0.050 |
Why?
|
| Platinum | 1 | 2004 | 222 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 2889 | 0.050 |
Why?
|
| Leukemia, T-Cell | 1 | 2003 | 101 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 2 | 2008 | 998 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2014 | 710 | 0.050 |
Why?
|
| Ozone | 2 | 2004 | 490 | 0.050 |
Why?
|
| Granulocyte Precursor Cells | 2 | 2012 | 49 | 0.050 |
Why?
|
| Air Pollutants, Occupational | 2 | 2008 | 409 | 0.050 |
Why?
|
| Retinal Diseases | 1 | 1989 | 710 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2017 | 5926 | 0.050 |
Why?
|
| Heart Failure | 3 | 2023 | 11860 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 5 | 2006 | 247 | 0.050 |
Why?
|
| RNA Splicing | 2 | 2021 | 903 | 0.050 |
Why?
|
| Cryoprotective Agents | 1 | 2003 | 128 | 0.050 |
Why?
|
| Receptors, Chemokine | 2 | 2005 | 652 | 0.050 |
Why?
|
| Vaccines, DNA | 1 | 2024 | 280 | 0.050 |
Why?
|
| Liver Failure | 1 | 2004 | 252 | 0.050 |
Why?
|
| Interleukin-15 | 3 | 2011 | 185 | 0.050 |
Why?
|
| Cell Lineage | 4 | 2016 | 2574 | 0.050 |
Why?
|
| Directly Observed Therapy | 1 | 2003 | 139 | 0.050 |
Why?
|
| Asbestos | 1 | 2004 | 251 | 0.050 |
Why?
|
| Esophageal Neoplasms | 3 | 1999 | 1675 | 0.050 |
Why?
|
| Sunlight | 1 | 2024 | 337 | 0.050 |
Why?
|
| Luciferases | 1 | 2004 | 712 | 0.050 |
Why?
|
| Antibodies, Heterophile | 2 | 1999 | 128 | 0.050 |
Why?
|
| Tamoxifen | 3 | 2018 | 968 | 0.050 |
Why?
|
| Epidemiologic Methods | 4 | 2011 | 1337 | 0.050 |
Why?
|
| Sperm Motility | 1 | 2003 | 266 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 906 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2014 | 551 | 0.050 |
Why?
|
| Infant, Newborn | 10 | 2013 | 26410 | 0.050 |
Why?
|
| Tumor Burden | 3 | 2013 | 1913 | 0.050 |
Why?
|
| Exons | 3 | 2014 | 2392 | 0.050 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2022 | 153 | 0.050 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 283 | 0.050 |
Why?
|
| Lod Score | 2 | 2001 | 600 | 0.050 |
Why?
|
| Acetamides | 1 | 2003 | 260 | 0.050 |
Why?
|
| Spleen | 3 | 2018 | 2295 | 0.050 |
Why?
|
| Cell Count | 3 | 2014 | 1833 | 0.050 |
Why?
|
| Leukopoiesis | 1 | 2001 | 54 | 0.050 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 3211 | 0.050 |
Why?
|
| Sensitivity and Specificity | 9 | 2017 | 14736 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2004 | 596 | 0.050 |
Why?
|
| Mechlorethamine | 2 | 2016 | 129 | 0.050 |
Why?
|
| Amino Acid Sequence | 5 | 2017 | 13425 | 0.050 |
Why?
|
| Sulfites | 2 | 2014 | 83 | 0.050 |
Why?
|
| Homeostasis | 3 | 2020 | 3349 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 1683 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2014 | 453 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 320 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2002 | 260 | 0.050 |
Why?
|
| Daptomycin | 1 | 2021 | 71 | 0.050 |
Why?
|
| World Health Organization | 2 | 2018 | 1327 | 0.050 |
Why?
|
| Integrases | 2 | 2018 | 520 | 0.050 |
Why?
|
| Cross-Sectional Studies | 8 | 2018 | 26373 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2004 | 383 | 0.050 |
Why?
|
| Ataxia Telangiectasia | 2 | 1999 | 107 | 0.050 |
Why?
|
| Smoking | 5 | 2022 | 9109 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2004 | 358 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2015 | 3985 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2008 | 964 | 0.050 |
Why?
|
| Viral Matrix Proteins | 2 | 2012 | 193 | 0.050 |
Why?
|
| Prednisolone | 1 | 2002 | 327 | 0.050 |
Why?
|
| Drug Hypersensitivity | 1 | 2010 | 923 | 0.050 |
Why?
|
| Colorectal Neoplasms | 2 | 2017 | 6969 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2024 | 12457 | 0.050 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2012 | 1889 | 0.050 |
Why?
|
| Telomere-Binding Proteins | 1 | 2021 | 121 | 0.050 |
Why?
|
| Immunomodulation | 2 | 2018 | 549 | 0.050 |
Why?
|
| Phosphotyrosine | 2 | 2016 | 458 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 1126 | 0.040 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2000 | 49 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2007 | 1501 | 0.040 |
Why?
|
| Analysis of Variance | 6 | 2008 | 6238 | 0.040 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2002 | 195 | 0.040 |
Why?
|
| Industrial Waste | 1 | 2000 | 24 | 0.040 |
Why?
|
| Chromatin | 2 | 2023 | 2967 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 1082 | 0.040 |
Why?
|
| Fuel Oils | 1 | 2000 | 35 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 2038 | 0.040 |
Why?
|
| Cancer Care Facilities | 2 | 2014 | 424 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2004 | 1468 | 0.040 |
Why?
|
| Quebec | 1 | 2020 | 139 | 0.040 |
Why?
|
| Vanadium | 1 | 2000 | 54 | 0.040 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 2000 | 45 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 2202 | 0.040 |
Why?
|
| Boron Compounds | 1 | 2022 | 196 | 0.040 |
Why?
|
| Graft vs Tumor Effect | 1 | 2000 | 68 | 0.040 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2000 | 67 | 0.040 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 221 | 0.040 |
Why?
|
| Demography | 2 | 2023 | 1642 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2011 | 411 | 0.040 |
Why?
|
| Genetic Association Studies | 3 | 2014 | 2741 | 0.040 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2000 | 66 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3707 | 0.040 |
Why?
|
| Lung Diseases | 2 | 2008 | 1925 | 0.040 |
Why?
|
| Estradiol | 1 | 2007 | 1952 | 0.040 |
Why?
|
| Embryo, Nonmammalian | 3 | 2009 | 911 | 0.040 |
Why?
|
| Citrates | 1 | 2000 | 134 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2007 | 899 | 0.040 |
Why?
|
| HIV-1 | 1 | 2017 | 6963 | 0.040 |
Why?
|
| Ricin | 1 | 1999 | 70 | 0.040 |
Why?
|
| Mice, Nude | 5 | 2005 | 3630 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2020 | 173 | 0.040 |
Why?
|
| Medicare | 3 | 2022 | 6881 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1998 | 564 | 0.040 |
Why?
|
| South America | 1 | 2019 | 180 | 0.040 |
Why?
|
| MART-1 Antigen | 2 | 2011 | 62 | 0.040 |
Why?
|
| Complementarity Determining Regions | 1 | 2000 | 150 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1999 | 977 | 0.040 |
Why?
|
| Spermatozoa | 1 | 2003 | 631 | 0.040 |
Why?
|
| Drosophila Proteins | 2 | 1999 | 1713 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 200 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2012 | 190 | 0.040 |
Why?
|
| Stomatitis | 1 | 2002 | 271 | 0.040 |
Why?
|
| Age of Onset | 1 | 2006 | 3345 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2012 | 5151 | 0.040 |
Why?
|
| Melphalan | 1 | 2020 | 421 | 0.040 |
Why?
|
| Vegetables | 1 | 2004 | 1200 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2004 | 971 | 0.040 |
Why?
|
| Immunotoxins | 1 | 1999 | 175 | 0.040 |
Why?
|
| Naphthalimides | 2 | 2015 | 22 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 370 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2007 | 3440 | 0.040 |
Why?
|
| HLA-DQ Antigens | 1 | 1999 | 190 | 0.040 |
Why?
|
| Secondary Prevention | 4 | 2011 | 1476 | 0.040 |
Why?
|
| Environmental Exposure | 2 | 2004 | 4528 | 0.040 |
Why?
|
| Random Allocation | 3 | 2016 | 2397 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2001 | 660 | 0.040 |
Why?
|
| Chemokine CXCL10 | 2 | 2011 | 311 | 0.040 |
Why?
|
| Radiotherapy | 3 | 2013 | 1509 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2002 | 752 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2004 | 853 | 0.040 |
Why?
|
| Radiation, Ionizing | 2 | 2012 | 252 | 0.040 |
Why?
|
| Flavonoids | 1 | 2002 | 447 | 0.040 |
Why?
|
| Heart | 1 | 2012 | 4449 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2015 | 683 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2018 | 94 | 0.040 |
Why?
|
| Cullin Proteins | 1 | 1999 | 180 | 0.040 |
Why?
|
| Pilot Projects | 9 | 2010 | 8730 | 0.040 |
Why?
|
| Papillomaviridae | 2 | 2013 | 1140 | 0.040 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2020 | 309 | 0.040 |
Why?
|
| Cytokines | 5 | 2018 | 7443 | 0.040 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2020 | 305 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 36849 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2020 | 10377 | 0.040 |
Why?
|
| Pandemics | 3 | 2024 | 8750 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2004 | 904 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2007 | 1389 | 0.040 |
Why?
|
| Receptors, CXCR4 | 2 | 2019 | 729 | 0.040 |
Why?
|
| Glycine | 1 | 2022 | 672 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2003 | 733 | 0.040 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1999 | 154 | 0.040 |
Why?
|
| Ukraine | 1 | 2018 | 151 | 0.040 |
Why?
|
| Histocompatibility | 1 | 1999 | 322 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2019 | 369 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 2018 | 125 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 4 | 2011 | 6228 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2004 | 848 | 0.040 |
Why?
|
| Myocardial Contraction | 2 | 2015 | 1527 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2005 | 2862 | 0.040 |
Why?
|
| Pyrroles | 2 | 2015 | 1126 | 0.040 |
Why?
|
| Chronic Disease | 5 | 2024 | 9380 | 0.040 |
Why?
|
| Prevotella | 1 | 2017 | 81 | 0.040 |
Why?
|
| Canada | 2 | 2015 | 2139 | 0.040 |
Why?
|
| Nuclear Family | 1 | 1999 | 311 | 0.040 |
Why?
|
| Community Health Services | 1 | 2003 | 659 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 2 | 2012 | 249 | 0.040 |
Why?
|
| Blood Component Removal | 3 | 2004 | 132 | 0.040 |
Why?
|
| Carotid Arteries | 2 | 2012 | 943 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2013 | 1743 | 0.040 |
Why?
|
| Calreticulin | 1 | 2018 | 115 | 0.040 |
Why?
|
| Species Specificity | 2 | 2014 | 2417 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2017 | 190 | 0.040 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 131 | 0.040 |
Why?
|
| Syndrome | 2 | 2015 | 3275 | 0.040 |
Why?
|
| Histone Demethylases | 1 | 2020 | 322 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 15939 | 0.040 |
Why?
|
| Heterozygote | 3 | 2015 | 2792 | 0.040 |
Why?
|
| Homozygote | 3 | 2015 | 1779 | 0.040 |
Why?
|
| Hydrolases | 1 | 2018 | 146 | 0.040 |
Why?
|
| Retroviridae | 3 | 2005 | 849 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2000 | 1141 | 0.040 |
Why?
|
| Imides | 1 | 1997 | 15 | 0.040 |
Why?
|
| Polydeoxyribonucleotides | 1 | 1998 | 136 | 0.040 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2018 | 160 | 0.040 |
Why?
|
| Bacteroides | 1 | 2017 | 165 | 0.040 |
Why?
|
| Automation | 1 | 2020 | 588 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2022 | 540 | 0.040 |
Why?
|
| Pheochromocytoma | 1 | 1999 | 328 | 0.040 |
Why?
|
| Genetic Testing | 3 | 1999 | 3587 | 0.040 |
Why?
|
| Progesterone | 1 | 2001 | 751 | 0.040 |
Why?
|
| Models, Genetic | 3 | 2007 | 3442 | 0.040 |
Why?
|
| Ligands | 2 | 2018 | 3283 | 0.040 |
Why?
|
| Protein Stability | 1 | 2019 | 579 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2021 | 1081 | 0.030 |
Why?
|
| Heart Septal Defects | 1 | 2018 | 191 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 346 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2020 | 462 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2022 | 757 | 0.030 |
Why?
|
| Response Elements | 1 | 2018 | 308 | 0.030 |
Why?
|
| Forearm | 1 | 2019 | 428 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2022 | 775 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2010 | 687 | 0.030 |
Why?
|
| Heparin | 2 | 2021 | 1636 | 0.030 |
Why?
|
| Autophagy | 2 | 2018 | 1350 | 0.030 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2016 | 66 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 2019 | 856 | 0.030 |
Why?
|
| Family Health | 2 | 2012 | 1255 | 0.030 |
Why?
|
| Immune System | 2 | 2016 | 801 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 15652 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 2 | 2011 | 183 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 426 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2022 | 1020 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 2013 | 2298 | 0.030 |
Why?
|
| Megestrol | 1 | 1996 | 9 | 0.030 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 1998 | 220 | 0.030 |
Why?
|
| Air Pollution, Indoor | 1 | 2004 | 915 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 3681 | 0.030 |
Why?
|
| Stromal Cells | 2 | 2012 | 1337 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2018 | 370 | 0.030 |
Why?
|
| Uric Acid | 1 | 2022 | 806 | 0.030 |
Why?
|
| Health Behavior | 1 | 2008 | 2647 | 0.030 |
Why?
|
| Acyl Coenzyme A | 1 | 2016 | 56 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2016 | 213 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 720 | 0.030 |
Why?
|
| Histiocytic Sarcoma | 1 | 2016 | 40 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1998 | 896 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1765 | 0.030 |
Why?
|
| Immunity, Humoral | 2 | 2010 | 611 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 3612 | 0.030 |
Why?
|
| Lung | 2 | 2008 | 10087 | 0.030 |
Why?
|
| RNA Transport | 1 | 2015 | 43 | 0.030 |
Why?
|
| Haemophilus Vaccines | 1 | 1995 | 71 | 0.030 |
Why?
|
| Vomiting | 2 | 2012 | 655 | 0.030 |
Why?
|
| Stroke Volume | 2 | 2023 | 5620 | 0.030 |
Why?
|
| Trisomy | 2 | 2014 | 260 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2019 | 1502 | 0.030 |
Why?
|
| Life Tables | 4 | 1998 | 368 | 0.030 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2017 | 199 | 0.030 |
Why?
|
| Ketoglutaric Acids | 1 | 2016 | 76 | 0.030 |
Why?
|
| Marital Status | 1 | 2017 | 426 | 0.030 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 793 | 0.030 |
Why?
|
| Oxidation-Reduction | 2 | 2016 | 2225 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2016 | 192 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 14783 | 0.030 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2015 | 62 | 0.030 |
Why?
|
| Databases, Factual | 3 | 2017 | 8072 | 0.030 |
Why?
|
| Biological Products | 1 | 2024 | 934 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2011 | 1905 | 0.030 |
Why?
|
| Stomach Neoplasms | 2 | 1996 | 1481 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1999 | 1157 | 0.030 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 20 | 0.030 |
Why?
|
| Inflammation | 2 | 2015 | 10863 | 0.030 |
Why?
|
| Graft Survival | 5 | 2008 | 3900 | 0.030 |
Why?
|
| beta-Globins | 1 | 2015 | 112 | 0.030 |
Why?
|
| Paraffin | 1 | 2014 | 36 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2016 | 188 | 0.030 |
Why?
|
| Cytosine | 1 | 2016 | 213 | 0.030 |
Why?
|
| Antisickling Agents | 1 | 2015 | 72 | 0.030 |
Why?
|
| Research Personnel | 1 | 2020 | 590 | 0.030 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2017 | 166 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2018 | 470 | 0.030 |
Why?
|
| Algorithms | 4 | 2021 | 14154 | 0.030 |
Why?
|
| Estrogens | 1 | 2001 | 1534 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 153 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2011 | 20766 | 0.030 |
Why?
|
| RNA | 1 | 2004 | 2726 | 0.030 |
Why?
|
| rap GTP-Binding Proteins | 1 | 2014 | 24 | 0.030 |
Why?
|
| Antibodies | 1 | 2022 | 2425 | 0.030 |
Why?
|
| Immunity, Mucosal | 1 | 2018 | 493 | 0.030 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2003 | 939 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 417 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2000 | 748 | 0.030 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 1996 | 277 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2001 | 1507 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2006 | 2083 | 0.030 |
Why?
|
| Cell Division | 4 | 2004 | 4478 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2019 | 1011 | 0.030 |
Why?
|
| Automation, Laboratory | 1 | 2014 | 102 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2006 | 317 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2014 | 189 | 0.030 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2014 | 84 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 183 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 556 | 0.030 |
Why?
|
| Reference Values | 3 | 2011 | 4941 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 76 | 0.030 |
Why?
|
| Thiophenes | 1 | 2018 | 569 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 2003 | 1391 | 0.030 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2013 | 42 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 1995 | 334 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2014 | 118 | 0.030 |
Why?
|
| Bone Marrow Examination | 2 | 2005 | 154 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1999 | 736 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 1378 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2007 | 3443 | 0.030 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2013 | 29 | 0.030 |
Why?
|
| Receptors, Pituitary Hormone | 1 | 2013 | 29 | 0.030 |
Why?
|
| Cell Death | 1 | 2019 | 1681 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 306 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 1169 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 245 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 600 | 0.030 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2013 | 48 | 0.030 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 1994 | 239 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 2 | 1992 | 1767 | 0.030 |
Why?
|
| Bacterial Vaccines | 1 | 1995 | 400 | 0.030 |
Why?
|
| Logistic Models | 4 | 2014 | 13323 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 1995 | 304 | 0.030 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2013 | 125 | 0.030 |
Why?
|
| Tyrphostins | 1 | 2013 | 63 | 0.030 |
Why?
|
| Feces | 1 | 2020 | 1516 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2016 | 348 | 0.030 |
Why?
|
| Fenofibrate | 1 | 2013 | 87 | 0.030 |
Why?
|
| Gene Order | 1 | 2013 | 167 | 0.030 |
Why?
|
| Massachusetts | 3 | 2016 | 8902 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 361 | 0.030 |
Why?
|
| Goserelin | 1 | 1993 | 126 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2015 | 393 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1995 | 420 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1994 | 329 | 0.030 |
Why?
|
| Janus Kinase 3 | 1 | 2013 | 77 | 0.030 |
Why?
|
| Diet | 3 | 2007 | 8097 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1995 | 403 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2003 | 808 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2019 | 1161 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1995 | 582 | 0.030 |
Why?
|
| Taxoids | 1 | 1996 | 668 | 0.030 |
Why?
|
| Interferon Type I | 1 | 1997 | 569 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2013 | 314 | 0.030 |
Why?
|
| Metalloproteins | 2 | 2004 | 98 | 0.030 |
Why?
|
| Nitriles | 1 | 2018 | 984 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 3439 | 0.030 |
Why?
|
| Limulus Test | 1 | 1992 | 19 | 0.030 |
Why?
|
| Benchmarking | 1 | 2019 | 1058 | 0.030 |
Why?
|
| Iron Overload | 1 | 2015 | 246 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 731 | 0.030 |
Why?
|
| Ploidies | 1 | 2013 | 287 | 0.030 |
Why?
|
| Antibody Formation | 2 | 2010 | 1393 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 2013 | 328 | 0.030 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2012 | 94 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2016 | 499 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 359 | 0.020 |
Why?
|
| Organisms, Genetically Modified | 1 | 2012 | 63 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2019 | 1479 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2014 | 781 | 0.020 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2013 | 209 | 0.020 |
Why?
|
| Chromosome Duplication | 1 | 2012 | 76 | 0.020 |
Why?
|
| Overweight | 1 | 2023 | 2445 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2011 | 27 | 0.020 |
Why?
|
| F-Box Proteins | 1 | 2013 | 201 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2012 | 160 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 478 | 0.020 |
Why?
|
| Cyclosporine | 1 | 1994 | 779 | 0.020 |
Why?
|
| E2F Transcription Factors | 1 | 2012 | 270 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 313 | 0.020 |
Why?
|
| Laparotomy | 1 | 1994 | 458 | 0.020 |
Why?
|
| Cluster Analysis | 2 | 2012 | 2727 | 0.020 |
Why?
|
| Cryoultramicrotomy | 1 | 2011 | 16 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2013 | 254 | 0.020 |
Why?
|
| Cyclins | 2 | 2006 | 606 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2018 | 1218 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 2000 | 1490 | 0.020 |
Why?
|
| Mitotic Index | 1 | 2011 | 162 | 0.020 |
Why?
|
| Virus Integration | 1 | 2013 | 306 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 162 | 0.020 |
Why?
|
| Registries | 2 | 2020 | 8378 | 0.020 |
Why?
|
| Procarbazine | 2 | 2004 | 172 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2017 | 841 | 0.020 |
Why?
|
| Motor Neurons | 1 | 2016 | 872 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2012 | 275 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 504 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2016 | 1090 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 306 | 0.020 |
Why?
|
| Methylation | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Antigens, CD7 | 2 | 2001 | 29 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 2011 | 216 | 0.020 |
Why?
|
| Cause of Death | 3 | 2013 | 3728 | 0.020 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 161 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2013 | 348 | 0.020 |
Why?
|
| Equipment Design | 1 | 2019 | 3529 | 0.020 |
Why?
|
| Caspase 3 | 2 | 2004 | 731 | 0.020 |
Why?
|
| Pedigree | 2 | 2012 | 4545 | 0.020 |
Why?
|
| Radiotherapy Dosage | 3 | 2004 | 2920 | 0.020 |
Why?
|
| Microsatellite Repeats | 2 | 2005 | 784 | 0.020 |
Why?
|
| Ankle Brachial Index | 1 | 2011 | 163 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2011 | 138 | 0.020 |
Why?
|
| p-Methoxy-N-methylphenethylamine | 1 | 2010 | 41 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2010 | 2636 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 378 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2018 | 1609 | 0.020 |
Why?
|
| Age Determination by Skeleton | 1 | 2011 | 126 | 0.020 |
Why?
|
| Mesna | 2 | 2004 | 62 | 0.020 |
Why?
|
| Ketotifen | 1 | 2010 | 24 | 0.020 |
Why?
|
| Protein Transport | 1 | 2016 | 1958 | 0.020 |
Why?
|
| Glycolysis | 1 | 2015 | 838 | 0.020 |
Why?
|
| Inverted Repeat Sequences | 1 | 2010 | 60 | 0.020 |
Why?
|
| Amino Acids | 1 | 2017 | 1716 | 0.020 |
Why?
|
| Pain | 2 | 2023 | 5102 | 0.020 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1991 | 106 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2012 | 425 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2011 | 320 | 0.020 |
Why?
|
| Carrier Proteins | 2 | 2004 | 4940 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 2014 | 538 | 0.020 |
Why?
|
| Dimerization | 2 | 2006 | 886 | 0.020 |
Why?
|
| Insulin | 1 | 2005 | 6608 | 0.020 |
Why?
|
| Mediastinum | 1 | 2012 | 272 | 0.020 |
Why?
|
| Erythroid Precursor Cells | 1 | 2011 | 212 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 2010 | 417 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2010 | 122 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2010 | 238 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2014 | 489 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2012 | 530 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2011 | 168 | 0.020 |
Why?
|
| Twins | 1 | 2012 | 339 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 628 | 0.020 |
Why?
|
| Histamine H1 Antagonists | 1 | 2010 | 101 | 0.020 |
Why?
|
| Models, Animal | 1 | 2017 | 2124 | 0.020 |
Why?
|
| Caspases | 2 | 2004 | 880 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1998 | 1813 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2010 | 182 | 0.020 |
Why?
|
| Seasons | 2 | 2007 | 1526 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2003 | 491 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2013 | 704 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2010 | 198 | 0.020 |
Why?
|
| Codon | 2 | 2004 | 599 | 0.020 |
Why?
|
| Occupational Exposure | 3 | 2008 | 1817 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 1315 | 0.020 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2011 | 147 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2001 | 94 | 0.020 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2014 | 302 | 0.020 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2010 | 71 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1705 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2004 | 3541 | 0.020 |
Why?
|
| Air Pollutants | 1 | 2004 | 2900 | 0.020 |
Why?
|
| Angiopoietin-2 | 1 | 2010 | 173 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2004 | 1992 | 0.020 |
Why?
|
| Clinical Trials as Topic | 5 | 2010 | 8051 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 575 | 0.020 |
Why?
|
| DNA Probes | 2 | 2003 | 542 | 0.020 |
Why?
|
| Observer Variation | 1 | 2016 | 2623 | 0.020 |
Why?
|
| Endotoxins | 1 | 1992 | 520 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 1739 | 0.020 |
Why?
|
| Growth Plate | 1 | 2011 | 276 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2011 | 361 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 902 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2017 | 1410 | 0.020 |
Why?
|
| Educational Status | 1 | 2017 | 2518 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2010 | 294 | 0.020 |
Why?
|
| Isoxazoles | 1 | 2011 | 233 | 0.020 |
Why?
|
| U937 Cells | 1 | 2009 | 260 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2010 | 380 | 0.020 |
Why?
|
| RNA-Binding Proteins | 2 | 2009 | 1883 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2013 | 634 | 0.020 |
Why?
|
| AIDS-Related Complex | 1 | 1989 | 107 | 0.020 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 4981 | 0.020 |
Why?
|
| Calgranulin A | 1 | 2009 | 81 | 0.020 |
Why?
|
| Cholangiocarcinoma | 1 | 1995 | 562 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2011 | 577 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2002 | 225 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3631 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 1995 | 616 | 0.020 |
Why?
|
| Hemostasis | 1 | 2012 | 468 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 1998 | 1598 | 0.020 |
Why?
|
| Immunodominant Epitopes | 1 | 2010 | 244 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 809 | 0.020 |
Why?
|
| Humerus | 1 | 1991 | 273 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 414 | 0.020 |
Why?
|
| Indazoles | 1 | 1990 | 305 | 0.020 |
Why?
|
| Peroxidase | 2 | 2003 | 609 | 0.020 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 7145 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 2394 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 1998 | 2073 | 0.020 |
Why?
|
| Boston | 2 | 2015 | 9371 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 1990 | 213 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2011 | 824 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2019 | 2894 | 0.020 |
Why?
|
| Antigens, CD20 | 2 | 2003 | 199 | 0.020 |
Why?
|
| Quinolines | 1 | 2014 | 768 | 0.020 |
Why?
|
| Income | 1 | 2017 | 1877 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2012 | 992 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2019 | 2906 | 0.020 |
Why?
|
| Nucleic Acids | 1 | 2011 | 189 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2010 | 244 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2012 | 876 | 0.020 |
Why?
|
| Welding | 1 | 2008 | 89 | 0.020 |
Why?
|
| Social Class | 1 | 2017 | 2008 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2012 | 566 | 0.020 |
Why?
|
| Self-Examination | 1 | 2008 | 71 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 662 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 2010 | 346 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 1375 | 0.020 |
Why?
|
| Imidazoles | 1 | 2014 | 1168 | 0.020 |
Why?
|
| Cross-Priming | 1 | 2008 | 75 | 0.020 |
Why?
|
| Placebos | 2 | 2002 | 1668 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1994 | 799 | 0.020 |
Why?
|
| Multiple Organ Failure | 2 | 2002 | 387 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 604 | 0.020 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2007 | 25 | 0.020 |
Why?
|
| Attachment Sites, Microbiological | 1 | 2007 | 26 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2011 | 541 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 2002 | 317 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2002 | 287 | 0.020 |
Why?
|
| Rheumatic Diseases | 1 | 2015 | 662 | 0.020 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 180 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2011 | 583 | 0.020 |
Why?
|
| Blood Group Incompatibility | 1 | 2008 | 134 | 0.020 |
Why?
|
| Gills | 1 | 2007 | 21 | 0.020 |
Why?
|
| Developing Countries | 2 | 2015 | 2903 | 0.020 |
Why?
|
| Cell Size | 1 | 2009 | 626 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2008 | 287 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2013 | 1184 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2011 | 829 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2011 | 549 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 3520 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2010 | 891 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 1342 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2002 | 2661 | 0.020 |
Why?
|
| Living Donors | 1 | 2011 | 650 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 1999 | 228 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1992 | 916 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2016 | 3663 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2007 | 318 | 0.020 |
Why?
|
| Epigenomics | 1 | 2012 | 959 | 0.020 |
Why?
|
| Filgrastim | 2 | 1998 | 131 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 2596 | 0.020 |
Why?
|
| Multigene Family | 1 | 2010 | 1082 | 0.020 |
Why?
|
| Anthropometry | 1 | 2011 | 1343 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 623 | 0.020 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2006 | 40 | 0.020 |
Why?
|
| Microinjections | 1 | 2007 | 323 | 0.020 |
Why?
|
| Graft Rejection | 2 | 2011 | 4505 | 0.020 |
Why?
|
| Cyclin D2 | 1 | 2006 | 98 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 2177 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2007 | 1305 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 1355 | 0.020 |
Why?
|
| Pregnancy | 4 | 2020 | 30198 | 0.020 |
Why?
|
| Contrast Media | 1 | 2019 | 5337 | 0.020 |
Why?
|
| Receptors, Erythropoietin | 1 | 2006 | 144 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 650 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1880 | 0.020 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2016 | 1666 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 3092 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1993 | 936 | 0.020 |
Why?
|
| Inhalation Exposure | 1 | 2008 | 431 | 0.020 |
Why?
|
| Thymopoietins | 1 | 2005 | 10 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 2536 | 0.020 |
Why?
|
| Causality | 1 | 2012 | 1255 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 1320 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 1248 | 0.020 |
Why?
|
| Cyclin B | 1 | 2005 | 104 | 0.020 |
Why?
|
| Eosinophils | 2 | 2002 | 953 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2009 | 614 | 0.020 |
Why?
|
| Genetic Engineering | 2 | 2003 | 936 | 0.020 |
Why?
|
| Employment | 1 | 2012 | 1116 | 0.020 |
Why?
|
| Regression Analysis | 3 | 2003 | 6350 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2006 | 268 | 0.020 |
Why?
|
| Endostatins | 1 | 2005 | 168 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2010 | 762 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2010 | 538 | 0.020 |
Why?
|
| Poverty | 1 | 2017 | 2721 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1795 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5511 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2005 | 195 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 1752 | 0.020 |
Why?
|
| Adenosine Deaminase | 1 | 2007 | 252 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 1445 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 2877 | 0.010 |
Why?
|
| Premenopause | 1 | 2009 | 1039 | 0.010 |
Why?
|
| Body Height | 1 | 2011 | 1568 | 0.010 |
Why?
|
| S Phase | 1 | 2006 | 423 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2015 | 2598 | 0.010 |
Why?
|
| G1 Phase | 1 | 2006 | 402 | 0.010 |
Why?
|
| Mycoplasma | 1 | 2005 | 147 | 0.010 |
Why?
|
| Binding Sites | 1 | 2013 | 6018 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2004 | 42 | 0.010 |
Why?
|
| Software | 1 | 1999 | 4452 | 0.010 |
Why?
|
| Femur | 1 | 1991 | 1311 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 2004 | 102 | 0.010 |
Why?
|
| Immunomagnetic Separation | 1 | 2004 | 79 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 9063 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2004 | 184 | 0.010 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 1281 | 0.010 |
Why?
|
| Pancytopenia | 1 | 2005 | 102 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4874 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 1902 | 0.010 |
Why?
|
| Feedback, Physiological | 1 | 2006 | 481 | 0.010 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 13019 | 0.010 |
Why?
|
| VDJ Recombinases | 1 | 2004 | 84 | 0.010 |
Why?
|
| Tennessee | 1 | 2004 | 123 | 0.010 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2004 | 89 | 0.010 |
Why?
|
| Breast | 1 | 2013 | 1975 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2004 | 106 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2004 | 423 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 466 | 0.010 |
Why?
|
| Cholesterol | 1 | 2013 | 2912 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2006 | 518 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 2201 | 0.010 |
Why?
|
| Solutions | 1 | 2004 | 409 | 0.010 |
Why?
|
| Mortality | 2 | 2005 | 2917 | 0.010 |
Why?
|
| Uterine Diseases | 1 | 2004 | 108 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2003 | 261 | 0.010 |
Why?
|
| Centromere | 1 | 2004 | 215 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2004 | 185 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2003 | 48 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 5375 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3107 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1998 | 642 | 0.010 |
Why?
|
| Codon, Nonsense | 1 | 2005 | 287 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2783 | 0.010 |
Why?
|
| Medicaid | 1 | 2017 | 2842 | 0.010 |
Why?
|
| Fluorescence | 1 | 2006 | 760 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2004 | 402 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2005 | 595 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2004 | 229 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2003 | 130 | 0.010 |
Why?
|
| Perforin | 1 | 2003 | 167 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 1371 | 0.010 |
Why?
|
| Prevalence | 2 | 2012 | 15868 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 1658 | 0.010 |
Why?
|
| Chromosome Disorders | 2 | 1998 | 499 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2013 | 2588 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2007 | 1526 | 0.010 |
Why?
|
| Protein Engineering | 1 | 2006 | 550 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2008 | 1186 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2005 | 611 | 0.010 |
Why?
|
| Phylogeny | 1 | 2010 | 2842 | 0.010 |
Why?
|
| Sarcoma | 1 | 2014 | 1806 | 0.010 |
Why?
|
| Health Services | 1 | 2008 | 756 | 0.010 |
Why?
|
| RNA Stability | 1 | 2004 | 321 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2004 | 343 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1989 | 2363 | 0.010 |
Why?
|
| Reproduction | 1 | 2007 | 646 | 0.010 |
Why?
|
| Transfection | 2 | 2002 | 5758 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 816 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2004 | 2911 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2002 | 104 | 0.010 |
Why?
|
| Weight Gain | 1 | 2012 | 2358 | 0.010 |
Why?
|
| Methods | 1 | 2002 | 1067 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 484 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2003 | 249 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 2004 | 474 | 0.010 |
Why?
|
| Leucovorin | 1 | 2004 | 643 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 1666 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 11220 | 0.010 |
Why?
|
| tRNA Methyltransferases | 1 | 2002 | 50 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2003 | 432 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1994 | 2256 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2011 | 2324 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 178 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2002 | 310 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 682 | 0.010 |
Why?
|
| Data Collection | 1 | 2011 | 3324 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 2003 | 574 | 0.010 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2001 | 50 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2005 | 504 | 0.010 |
Why?
|
| Asthma | 1 | 2001 | 6281 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4360 | 0.010 |
Why?
|
| Physical Examination | 1 | 2008 | 1262 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 1640 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 2068 | 0.010 |
Why?
|
| Kidney | 2 | 2007 | 7063 | 0.010 |
Why?
|
| Melatonin | 1 | 2007 | 669 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 2056 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2000 | 38 | 0.010 |
Why?
|
| Radiography | 1 | 2012 | 6993 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2003 | 391 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2011 | 2058 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 13082 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2002 | 306 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2011 | 3230 | 0.010 |
Why?
|
| Chemokines | 1 | 2005 | 962 | 0.010 |
Why?
|
| NAD+ Nucleosidase | 1 | 2000 | 43 | 0.010 |
Why?
|
| Alkaloids | 1 | 2002 | 192 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 299 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2002 | 379 | 0.010 |
Why?
|
| Receptors, CCR2 | 1 | 2001 | 216 | 0.010 |
Why?
|
| Professional Competence | 1 | 2004 | 430 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 2004 | 900 | 0.010 |
Why?
|
| Pyridones | 1 | 2006 | 818 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1204 | 0.010 |
Why?
|
| Longevity | 1 | 2008 | 1077 | 0.010 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2000 | 87 | 0.010 |
Why?
|
| Healthy Worker Effect | 1 | 2000 | 29 | 0.010 |
Why?
|
| Temperature | 1 | 2007 | 2234 | 0.010 |
Why?
|
| Mitosis | 1 | 2005 | 1190 | 0.010 |
Why?
|
| Body Fluids | 1 | 2002 | 321 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 1524 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2005 | 1956 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 6209 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 2267 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2001 | 420 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2005 | 1042 | 0.010 |
Why?
|
| Decision Making | 2 | 2004 | 3953 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2002 | 453 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 3859 | 0.010 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2000 | 133 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 881 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2001 | 457 | 0.010 |
Why?
|
| Peru | 1 | 2003 | 890 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 413 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2005 | 1078 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 1337 | 0.010 |
Why?
|
| Nose Diseases | 1 | 2000 | 79 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2007 | 1841 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1999 | 326 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2004 | 863 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2003 | 1093 | 0.010 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 1999 | 40 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 3779 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 3412 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 1926 | 0.010 |
Why?
|
| Liver | 1 | 2015 | 7570 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 1647 | 0.010 |
Why?
|
| Receptors, Interleukin-12 | 1 | 1998 | 26 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2003 | 887 | 0.010 |
Why?
|
| Fertility | 1 | 2003 | 772 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2008 | 1417 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2007 | 2127 | 0.010 |
Why?
|
| Tyrosine | 1 | 2003 | 1428 | 0.010 |
Why?
|
| Immunity | 1 | 2004 | 1003 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 3236 | 0.010 |
Why?
|
| Microspheres | 1 | 2002 | 789 | 0.010 |
Why?
|
| Pharyngitis | 1 | 2000 | 222 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1998 | 108 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2002 | 664 | 0.010 |
Why?
|
| Bone Density | 1 | 2011 | 3559 | 0.010 |
Why?
|
| Air Pollution | 1 | 1992 | 2363 | 0.010 |
Why?
|
| Child Behavior | 1 | 2004 | 865 | 0.010 |
Why?
|
| Chondroitin Sulfates | 1 | 1998 | 174 | 0.010 |
Why?
|
| Menstrual Cycle | 1 | 2001 | 545 | 0.010 |
Why?
|
| Cerebellar Diseases | 1 | 2000 | 221 | 0.010 |
Why?
|
| Regeneration | 1 | 2007 | 1525 | 0.010 |
Why?
|
| Stem Cells | 1 | 2011 | 3537 | 0.010 |
Why?
|
| Neprilysin | 1 | 2001 | 487 | 0.010 |
Why?
|
| WT1 Proteins | 1 | 1998 | 184 | 0.010 |
Why?
|
| Health Surveys | 1 | 2008 | 4056 | 0.010 |
Why?
|
| Thalassemia | 1 | 1998 | 267 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1998 | 849 | 0.010 |
Why?
|
| Fluoxymesterone | 1 | 1997 | 12 | 0.010 |
Why?
|
| Radiation Oncology | 1 | 2004 | 572 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1997 | 99 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 1760 | 0.010 |
Why?
|
| Sputum | 1 | 2000 | 511 | 0.010 |
Why?
|
| Environmental Monitoring | 1 | 2004 | 1463 | 0.010 |
Why?
|
| Myocardium | 1 | 2010 | 4788 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 1998 | 243 | 0.010 |
Why?
|
| Comorbidity | 1 | 2012 | 10588 | 0.010 |
Why?
|
| Parents | 1 | 2011 | 3596 | 0.010 |
Why?
|
| Quality Control | 1 | 2000 | 833 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2003 | 1595 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 2000 | 336 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2236 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2004 | 2437 | 0.010 |
Why?
|
| Bilirubin | 1 | 1998 | 438 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 1999 | 877 | 0.010 |
Why?
|
| Megestrol Acetate | 1 | 1996 | 18 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2003 | 1955 | 0.010 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 1995 | 25 | 0.010 |
Why?
|
| Cough | 1 | 2000 | 599 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8541 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2001 | 942 | 0.010 |
Why?
|
| Respiratory Sounds | 1 | 2000 | 702 | 0.010 |
Why?
|
| Urogenital Abnormalities | 1 | 1998 | 255 | 0.010 |
Why?
|
| Potassium | 1 | 2000 | 1319 | 0.010 |
Why?
|
| Exanthema | 1 | 2000 | 503 | 0.010 |
Why?
|
| Meningococcal Vaccines | 1 | 1995 | 96 | 0.010 |
Why?
|
| Antigens | 1 | 2000 | 1443 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1994 | 98 | 0.010 |
Why?
|
| Rats | 1 | 2011 | 23833 | 0.010 |
Why?
|
| Bacterial Capsules | 1 | 1995 | 247 | 0.010 |
Why?
|
| Health Status | 1 | 2008 | 4094 | 0.010 |
Why?
|
| Hyaluronic Acid | 1 | 1998 | 487 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 5890 | 0.010 |
Why?
|
| Cell Communication | 1 | 2002 | 1660 | 0.010 |
Why?
|
| Sodium | 1 | 2000 | 1594 | 0.010 |
Why?
|
| Medical Records | 1 | 2000 | 1413 | 0.010 |
Why?
|
| Dehydration | 1 | 1996 | 216 | 0.010 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1999 | 605 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1994 | 372 | 0.010 |
Why?
|
| Hospitalization | 1 | 2014 | 10844 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2001 | 2205 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2004 | 3579 | 0.010 |
Why?
|
| Lymphography | 1 | 1994 | 189 | 0.010 |
Why?
|
| Calcineurin | 1 | 1994 | 236 | 0.010 |
Why?
|
| Interferons | 1 | 1997 | 717 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 3411 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 6566 | 0.010 |
Why?
|
| Astrocytoma | 1 | 1998 | 780 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1996 | 410 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1998 | 2931 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 2819 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1998 | 1163 | 0.010 |
Why?
|
| Amniocentesis | 1 | 1992 | 116 | 0.010 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1992 | 91 | 0.010 |
Why?
|
| Rhinitis | 1 | 2000 | 751 | 0.010 |
Why?
|
| Carboplatin | 1 | 1995 | 799 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 1992 | 227 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2000 | 1568 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2003 | 2784 | 0.010 |
Why?
|
| Mitolactol | 1 | 1991 | 13 | 0.010 |
Why?
|
| Thiotepa | 1 | 1991 | 66 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1993 | 726 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 3267 | 0.010 |
Why?
|
| Axilla | 1 | 1993 | 628 | 0.010 |
Why?
|
| Pregnancy, High-Risk | 1 | 1991 | 121 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2000 | 2421 | 0.010 |
Why?
|
| Hematocrit | 1 | 1991 | 625 | 0.010 |
Why?
|
| Aerosols | 1 | 1992 | 637 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1993 | 708 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 1994 | 961 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1991 | 681 | 0.000 |
Why?
|
| Aneuploidy | 1 | 1992 | 572 | 0.000 |
Why?
|
| Mastectomy | 1 | 1997 | 1851 | 0.000 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1991 | 737 | 0.000 |
Why?
|
| Maternal Age | 1 | 1991 | 809 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1992 | 2487 | 0.000 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 2257 | 0.000 |
Why?
|
| Neck | 1 | 1991 | 736 | 0.000 |
Why?
|
| Probability | 1 | 1991 | 2482 | 0.000 |
Why?
|
| Lymphatic Metastasis | 1 | 1993 | 2924 | 0.000 |
Why?
|
| Menopause | 1 | 1993 | 1653 | 0.000 |
Why?
|
| Receptors, Estrogen | 1 | 1993 | 2247 | 0.000 |
Why?
|
| Kinetics | 1 | 1992 | 6334 | 0.000 |
Why?
|
| HIV Infections | 1 | 2011 | 17575 | 0.000 |
Why?
|
| Gestational Age | 1 | 1992 | 3615 | 0.000 |
Why?
|
| Palliative Care | 1 | 1998 | 3643 | 0.000 |
Why?
|
| Sepsis | 1 | 1996 | 2601 | 0.000 |
Why?
|
| Length of Stay | 1 | 1994 | 6516 | 0.000 |
Why?
|
| Brain | 1 | 2007 | 27452 | 0.000 |
Why?
|